Cargando…
Pharmacoepigenetics in type 2 diabetes: is it clinically relevant?
Data generated over nearly two decades clearly demonstrate the importance of epigenetic modifications and mechanisms in the pathogenesis of type 2 diabetes. However, the role of pharmacoepigenetics in type 2 diabetes is less well established. The field of pharmacoepigenetics covers epigenetic biomar...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522755/ https://www.ncbi.nlm.nih.gov/pubmed/35307762 http://dx.doi.org/10.1007/s00125-022-05681-x |
_version_ | 1784800126435328000 |
---|---|
author | Ling, Charlotte |
author_facet | Ling, Charlotte |
author_sort | Ling, Charlotte |
collection | PubMed |
description | Data generated over nearly two decades clearly demonstrate the importance of epigenetic modifications and mechanisms in the pathogenesis of type 2 diabetes. However, the role of pharmacoepigenetics in type 2 diabetes is less well established. The field of pharmacoepigenetics covers epigenetic biomarkers that predict response to therapy, therapy-induced epigenetic alterations as well as epigenetic therapies including inhibitors of epigenetic enzymes. Not all individuals with type 2 diabetes respond to glucose-lowering therapies in the same way, and there is therefore a need for clinically useful biomarkers that discriminate responders from non-responders. Blood-based epigenetic biomarkers may be useful for this purpose. There is also a need for a better understanding of whether existing glucose-lowering therapies exert their function partly through therapy-induced epigenetic alterations. Finally, epigenetic enzymes may be drug targets for type 2 diabetes. Here, I discuss whether pharmacoepigenetics is clinically relevant for type 2 diabetes based on studies addressing this topic. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00125-022-05681-x. |
format | Online Article Text |
id | pubmed-9522755 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-95227552022-10-01 Pharmacoepigenetics in type 2 diabetes: is it clinically relevant? Ling, Charlotte Diabetologia Commentary Data generated over nearly two decades clearly demonstrate the importance of epigenetic modifications and mechanisms in the pathogenesis of type 2 diabetes. However, the role of pharmacoepigenetics in type 2 diabetes is less well established. The field of pharmacoepigenetics covers epigenetic biomarkers that predict response to therapy, therapy-induced epigenetic alterations as well as epigenetic therapies including inhibitors of epigenetic enzymes. Not all individuals with type 2 diabetes respond to glucose-lowering therapies in the same way, and there is therefore a need for clinically useful biomarkers that discriminate responders from non-responders. Blood-based epigenetic biomarkers may be useful for this purpose. There is also a need for a better understanding of whether existing glucose-lowering therapies exert their function partly through therapy-induced epigenetic alterations. Finally, epigenetic enzymes may be drug targets for type 2 diabetes. Here, I discuss whether pharmacoepigenetics is clinically relevant for type 2 diabetes based on studies addressing this topic. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00125-022-05681-x. Springer Berlin Heidelberg 2022-03-21 2022 /pmc/articles/PMC9522755/ /pubmed/35307762 http://dx.doi.org/10.1007/s00125-022-05681-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Commentary Ling, Charlotte Pharmacoepigenetics in type 2 diabetes: is it clinically relevant? |
title | Pharmacoepigenetics in type 2 diabetes: is it clinically relevant? |
title_full | Pharmacoepigenetics in type 2 diabetes: is it clinically relevant? |
title_fullStr | Pharmacoepigenetics in type 2 diabetes: is it clinically relevant? |
title_full_unstemmed | Pharmacoepigenetics in type 2 diabetes: is it clinically relevant? |
title_short | Pharmacoepigenetics in type 2 diabetes: is it clinically relevant? |
title_sort | pharmacoepigenetics in type 2 diabetes: is it clinically relevant? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522755/ https://www.ncbi.nlm.nih.gov/pubmed/35307762 http://dx.doi.org/10.1007/s00125-022-05681-x |
work_keys_str_mv | AT lingcharlotte pharmacoepigeneticsintype2diabetesisitclinicallyrelevant |